Compare ADMA Biologics Inc (ADMA) vs Rocket Lab USA Inc (RKLB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ADMA Biologics Inc vs Rocket Lab USA Inc — how do they compare? ADMA Biologics Inc trades at $9.88 (market cap $2.22B), while Rocket Lab USA Inc trades at $80.82 (market cap $50.01B). The key difference: Rocket Lab USA Inc is far larger — about 22.5× ADMA Biologics Inc's market cap, and Rocket Lab USA Inc is trading nearer its 52-week high, ADMA Biologics Inc nearer its low. Which is the better fit depends on your goals.
| ADMA | RKLB | |
|---|---|---|
Market Cap | $2.22B | $50.01B |
Sector | Health | Technology |
52-Week High | $20.38 | $150.23 |
52-Week Low | $7.60 | $39.48 |
Enterprise Value | $2.29B | $47.84B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.78, up 0.31% today, with a bullish technical signal from moving averages and strong fundamentals including a 32.98% net income margin and 41.9% ROE. Recent earnings show a mix of beats and misses, with Q3 2026 EPS expected at $0.19. The stock faces headwinds from multiple class-action lawsuits alleging securities fraud, as reported by news outlets in August 2026.
Outlook is cautiously optimistic due to robust profitability and analyst support, but legal risks and recent earnings volatility pose challenges. Investment opportunity hinges on legal resolution and sustained earnings growth, with risks including litigation outcomes and competitive pressures in the biologics sector.
Rocket Lab (RKLB) trades at $81.17, up 1.41% today, showing strong momentum with a bullish technical outlook. The company reported record Q2 2026 revenue of $601.8M but missed EPS expectations, while maintaining a massive $2.36B backlog. Analysts remain overwhelmingly bullish with a $118 consensus target, though valuation metrics appear stretched with a P/S ratio of 60.8.
The stock offers significant upside potential driven by Neutron rocket development and growing space industry demand, but faces execution risks including margin pressures and cash burn. Near-term catalysts include the Neutron launch timeline and Iridium acquisition, though high valuation multiples require flawless execution to justify current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ADMA Biologics Inc
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →About Rocket Lab USA Inc
Rocket Lab USA, Inc. is an aerospace manufacturer and small-satellite launch service provider. The company specializes in developing rockets for orbital launch, including its flagship *Electron* vehicle, and is developing the next-generation, reusable *Neutron* rocket. Beyond launch services, Rocket Lab also offers satellite design, manufacturing, and spacecraft component solutions, positioning itself as an end-to-end provider for the space industry.
Read more on RKLB →
